{
 "as_of": "2026-11-06",
 "cmr": "se-cm-kg/SSME/SE0015988274",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# PILA PHARMA AB (First North Sweden: SE0015988274) — research page\n\nAs of 2026-11-06 · se-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is PILA PHARMA AB, listed on First North Sweden under ticker SE0015988274. Its ISIN is SE0015988274 and its LEI is 6488Z7WG18Q0ZN0V0262. The security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 35 filings in the twelve months to 2026-11-06, across 28 filing days. The median gap between filing days is 11 days. The latest filing is dated 2026-11-02, is of type Investor News, and is 4 days before the record date. The median gap between filing days for First North Sweden is 11 days across 325 issuers, the median filings count is 21, and the median latency is 7 days. The sector median is not on the record.\n\n## Auditor\n\nThe auditor of record is not on the record, and its location is not on the record. Auditor changes are not on the record, because the market's record does not carry a lifecycle type map for this register.\n\n## Events and halts\n\nThe record does not carry listing, delisting, name change, domicile change or segment move events, because the market's register has no lifecycle type map. The halt flag is listed, not halted.\n\n## Orderability\n\nThe orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nThe issuer's investor-relations page names 8 research houses: Redeye Equity Research, AktieInfo Equity Research, AG Equity Research, Carlsquare Equity Research, Redeye Equity Research Sweden, AktieInfo Equity Research Denmark, AG Equity Research Sweden and Carlsquare Equity Research Sweden.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe market's vintage is not sealed. No issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began is not on the record.\n\n## Sources\n\n7 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://firds.esma.europa.eu/firds/ (identity.exchange)\n- https://mapping.gleif.org/api/v2/isin-lei/latest/download (identity.lei)\n- https://mcp.se-cm-kg.ai/events/SSME/SE0015988274 (the disclosure lines)\n- https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation (the halt flag)\n- https://se.eu-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://pilapharma.com/analyst-coverage/ (coverage)\n- https://mcp.se-cm-kg.ai/record/SSME/SE0015988274 (the record)\n",
 "market": "SE",
 "node": "se-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [],
   "live_record_began": null,
   "node_history_from": null,
   "node_years_sealed": [],
   "note": "the SE vintage is not sealed; the record is the live record as of 2026-11-06",
   "record_version": 1,
   "sealed": false
  },
  "auditor": {
   "auditor": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_firm_id": {
    "market": "SE",
    "state": "not_on_record"
   },
   "auditor_location": {
    "market": "SE",
    "state": "not_on_record"
   },
   "changes": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "cmr": "se-cm-kg/SSME/SE0015988274",
  "coverage": {
   "count": 8,
   "houses": [
    {
     "analyst": "Filip Einarsson",
     "house": "Redeye Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "December 17, 2021",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "John Stihøj",
     "house": "AktieInfo Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Axel Ljunghammer",
     "house": "AG Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Niklas Elmhammer",
     "house": "Carlsquare Equity Research",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "since": "June 3, 2026",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Filip Einarsson",
     "house": "Redeye Equity Research Sweden",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "John Stihøj",
     "house": "AktieInfo Equity Research Denmark",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Axel Ljunghammer",
     "house": "AG Equity Research Sweden",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    },
    {
     "analyst": "Niklas Elmhammer",
     "house": "Carlsquare Equity Research Sweden",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-12",
     "source": "https://pilapharma.com/analyst-coverage/",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://pilapharma.com/analyst-coverage/",
     "result": "read: 8 of 8 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-12",
   "since": "stated per house where the page states it",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 325,
     "median_cadence_gap_days": 11,
     "median_filings": 21,
     "median_latency_days": 7,
     "name": "First North Sweden"
    },
    "sector": {
     "market": "SE",
     "state": "not_on_record"
    }
   },
   "by_type": {
    "Annual financial report": 1,
    "Company Announcement": 8,
    "Corporate Action": 1,
    "Decisions of general meeting": 1,
    "Financial calendar": 1,
    "Financial statement release": 1,
    "Half year financial report": 1,
    "Inside information": 2,
    "Investor News": 17,
    "Notice to general meeting": 1,
    "Other information disclosed according to the rules of the Exchange": 1
   },
   "cadence_median_gap_days": 11,
   "filing_days": 28,
   "filings": 35,
   "latency_days": 4,
   "latest": [
    {
     "category": "Investor News",
     "date": "2026-11-02",
     "source": "https://view.news.eu.nasdaq.com/view?id=b0d94d5fdff31aefb4ed1a7856beee9b5&lang=en&src=listed",
     "title": "PILA PHARMA: TO PARTICIPATE AT BIO EUROPE, A PHARMA PARTNERING CONFERENCE IN COLOGNE, NOVEMBER 9-11, TO EXPAND PARTNERSHIP DIALOGUE AS CLINICAL DEVELOPMENT PROGRESSES",
     "type": "Investor News"
    },
    {
     "category": "Company Announcement",
     "date": "2026-10-12",
     "source": "https://view.news.eu.nasdaq.com/view?id=b113185c378ef984e1b98d2ea94e85d38&lang=en&src=listed",
     "title": "PILA PHARMA: FIRST SUBJECTS DOSED IN SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY",
     "type": "Company Announcement"
    },
    {
     "category": "Company Announcement",
     "date": "2026-09-30",
     "source": "https://view.news.eu.nasdaq.com/view?id=b287c8eb60831249208352c1e96ee82a6&lang=en&src=listed",
     "title": "PILA PHARMA: FIRST SUBJECT FIRST VISIT COMPLETED FOR SAFETY PART 1 OF PP-CT04, A CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY",
     "type": "Company Announcement"
    },
    {
     "category": "Company Announcement",
     "date": "2026-09-29",
     "source": "https://view.news.eu.nasdaq.com/view?id=b6c908456f2c66e65b1949457c049f50c&lang=en&src=listed",
     "title": "PILA PHARMA: FIRST CLINICAL SITE INITIATED AND ACTIVATED, ENROLLMENT COMMENCES FOR SAFETY PART 1 OF PP-CT04, A 12-WEEK CLINICAL TRIAL IN PEOPLE LIVING WITH OBESITY",
     "type": "Company Announcement"
    },
    {
     "category": "Investor News",
     "date": "2026-09-08",
     "source": "https://view.news.eu.nasdaq.com/view?id=b8817d5a9a259576235fd6e8cc99281af&lang=en&src=listed",
     "title": "PILA PHARMA: ALL RECENT H1 REPORT AND MANAGEMENT INTERVIEWS NOW ONLINE",
     "type": "Investor News"
    }
   ],
   "latest_filing_date": "2026-11-02",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0015988274",
   "window": {
    "from": "2025-11-06",
    "to": "2026-11-06"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "First North Sweden"
   },
   "isin": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0015988274"
   },
   "jurisdiction": {
    "market": "SE",
    "state": "not_on_record"
   },
   "lei": {
    "read_by": "GLEIF ISIN-to-LEI mapping file (daily), LEI by exact ISIN",
    "read_date": "2026-11-09",
    "read_date_basis": "the field",
    "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download (ISIN SE0015988274)",
    "state": "sourced",
    "value": "6488Z7WG18Q0ZN0V0262"
   },
   "name": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "PILA PHARMA AB"
   },
   "sector": {
    "market": "SE",
    "state": "not_on_record"
   },
   "security_type": {
    "market": "SE",
    "state": "not_on_record"
   },
   "segment": {
    "market": "SE",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "allooloo-cm-kg/eu-sources/se roster.py",
    "read_date": "2026-11-06",
    "read_date_basis": "the record version as_of",
    "source": "https://firds.esma.europa.eu/firds/ (ESMA FIRDS FULINS_E 2026-11-07: FULINS_E_20261107_01of02.zip, FULINS_E_20261107_02of02.zip)",
    "state": "sourced",
    "value": "SE0015988274"
   },
   "website": {
    "market": "SE",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "domicile_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "listing": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "name_change": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   },
   "segment_move": {
    "market": "SE",
    "reason": "no lifecycle type map for this register yet (SHELF-01: us and ca first)",
    "state": "not_on_record"
   }
  },
  "market": "SE",
  "node": "se-cm-kg",
  "numbers_hash": "sha256:c474d848892278c941ccbb0ac6d1cff3c195de02adaa6b51a31d56c0c6173f2e",
  "open_research": {
   "read_date": "2026-11-12",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://se.eu-cm-kg.ai/book/aio.json",
    "door": "https://se.eu-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/se/mifid-ii-product-governance/r1",
   "section": "se.aio.v5"
  },
  "record": {
   "as_of": "2026-11-06",
   "url": "https://mcp.se-cm-kg.ai/record/SSME/SE0015988274",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-09",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:c474d848892278c941ccbb0ac6d1cff3c195de02adaa6b51a31d56c0c6173f2e",
 "path": "/se/SSME/SE0015988274",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is PILA PHARMA AB, listed on First North Sweden under ticker SE0015988274. Its ISIN is SE0015988274 and its LEI is 6488Z7WG18Q0ZN0V0262. The security type, segment, sector and jurisdiction are not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 35 filings in the twelve months to 2026-11-06, across 28 filing days. The median gap between filing days is 11 days. The latest filing is dated 2026-11-02, is of type Investor News, and is 4 days before the record date. The median gap between filing days for First North Sweden is 11 days across 325 issuers, the median filings count is 21, and the median latency is 7 days. The sector median is not on the record.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is not on the record, and its location is not on the record. Auditor changes are not on the record, because the market's record does not carry a lifecycle type map for this register.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record does not carry listing, delisting, name change, domicile change or segment move events, because the market's register has no lifecycle type map. The halt flag is listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The orderability outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/se/mifid-ii-product-governance/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "The issuer's investor-relations page names 8 research houses: Redeye Equity Research, AktieInfo Equity Research, AG Equity Research, Carlsquare Equity Research, Redeye Equity Research Sweden, AktieInfo Equity Research Denmark, AG Equity Research Sweden and Carlsquare Equity Research Sweden.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The market's vintage is not sealed. No issuer years are sealed. The market's earliest sealed date is not on the record, and the live record began is not on the record.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "7 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://firds.esma.europa.eu/firds/"
  },
  {
   "for": "identity.lei",
   "source": "https://mapping.gleif.org/api/v2/isin-lei/latest/download"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.se-cm-kg.ai/events/SSME/SE0015988274"
  },
  {
   "for": "the halt flag",
   "source": "https://api.news.eu.nasdaq.com/news/query.action?globalGroup=exchangeNotice&globalName=ExchangenewsFilter|FirstNorthInformation"
  },
  {
   "for": "the orderability chapter",
   "source": "https://se.eu-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://pilapharma.com/analyst-coverage/"
  },
  {
   "for": "the record",
   "source": "https://mcp.se-cm-kg.ai/record/SSME/SE0015988274"
  }
 ],
 "title": "PILA PHARMA AB (SE0015988274) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}